Literature DB >> 26985288

Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb Family.

Natalia Milosevich1, Michael C Gignac1, James McFarlane1, Chakravarthi Simhadri1, Shanti Horvath1, Kevin D Daze1, Caitlin S Croft1, Aman Dheri1, Taylor T H Quon1, Sarah F Douglas1, Jeremy E Wulff1, Irina Paci1, Fraser Hof1.   

Abstract

The polycomb paralogs CBX2, CBX4, CBX6, CBX7, and CBX8 are epigenetic readers that rely on "aromatic cage" motifs to engage their partners' methyllysine side chains. Each CBX carries out distinct functions, yet each includes a highly similar methyllysine-reading chromodomain as a key element. CBX7 is the only chromodomain that has yet been targeted by chemical inhibition. We report a small set of peptidomimetic agents in which a simple chemical modification switches the ligands from one with promiscuity across all polycomb paralogs to one that provides selective inhibition of CBX6. The structural basis for this selectivity, which involves occupancy of a small hydrophobic pocket adjacent to the aromatic cage, was confirmed through molecular dynamics simulations. Our results demonstrate the increases in affinity and selectivity generated by ligands that engage extended regions of chromodomain binding surfaces.

Entities:  

Keywords:  CBX6; Epigenetics; Polycomb Group proteins; methyllysine reader proteins; peptidomimetics

Year:  2015        PMID: 26985288      PMCID: PMC4753544          DOI: 10.1021/acsmedchemlett.5b00378

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  35 in total

1.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand.

Authors:  Xinyi Huang
Journal:  J Biomol Screen       Date:  2003-02

2.  Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.

Authors:  Chun-Wa Chung; Anthony W Dean; James M Woolven; Paul Bamborough
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

3.  Identification of methyllysine peptides binding to chromobox protein homolog 6 chromodomain in the human proteome.

Authors:  Nan Li; Richard S L Stein; Wei He; Elizabeth Komives; Wei Wang
Journal:  Mol Cell Proteomics       Date:  2013-07-10       Impact factor: 5.911

4.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

5.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.

Authors:  Paul Bamborough; Hawa Diallo; Jonathan D Goodacre; Laurie Gordon; Antonia Lewis; Jonathan T Seal; David M Wilson; Michael D Woodrow; Chun-Wa Chung
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

6.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

7.  The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.

Authors:  Michelle A Camerino; Nan Zhong; Aiping Dong; Bradley M Dickson; Lindsey I James; Brandi M Baughman; Jacqueline L Norris; Dmitri B Kireev; William P Janzen; Cheryl H Arrowsmith; Stephen V Frye
Journal:  Medchemcomm       Date:  2013-11       Impact factor: 3.597

Review 8.  Privileged diazepine compounds and their emergence as bromodomain inhibitors.

Authors:  Steven G Smith; Roberto Sanchez; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2014-04-17

9.  Recognition and specificity determinants of the human cbx chromodomains.

Authors:  Lilia Kaustov; Hui Ouyang; Maria Amaya; Alexander Lemak; Nataliya Nady; Shili Duan; Gregory A Wasney; Zhihong Li; Masoud Vedadi; Matthieu Schapira; Jinrong Min; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

10.  Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin.

Authors:  Emily Bernstein; Elizabeth M Duncan; Osamu Masui; Jesus Gil; Edith Heard; C David Allis
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

View more
  24 in total

1.  Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing.

Authors:  Kimberly D Barnash; Kelsey N Lamb; Jacob I Stuckey; Jacqueline L Norris; Stephanie H Cholensky; Dmitri B Kireev; Stephen V Frye; Lindsey I James
Journal:  ACS Chem Biol       Date:  2016-07-14       Impact factor: 5.100

Review 2.  Pharmacological Modulation of Transcriptional Coregulators in Cancer.

Authors:  Timothy R Bishop; Yuxiang Zhang; Michael A Erb
Journal:  Trends Pharmacol Sci       Date:  2019-05-08       Impact factor: 14.819

3.  Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.

Authors:  Kimberly D Barnash; Juliana The; Jacqueline L Norris-Drouin; Stephanie H Cholensky; Beau M Worley; Fengling Li; Jacob I Stuckey; Peter J Brown; Masoud Vedadi; Cheryl H Arrowsmith; Stephen V Frye; Lindsey I James
Journal:  ACS Comb Sci       Date:  2017-02-22       Impact factor: 3.784

Review 4.  A chemical probe toolbox for dissecting the cancer epigenome.

Authors:  Jake Shortt; Christopher J Ott; Ricky W Johnstone; James E Bradner
Journal:  Nat Rev Cancer       Date:  2017-02-23       Impact factor: 60.716

Review 5.  Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.

Authors:  Nilesh Zaware; Ming-Ming Zhou
Journal:  Curr Opin Chem Biol       Date:  2017-07-06       Impact factor: 8.822

6.  Structure-Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains.

Authors:  Jacob I Stuckey; Catherine Simpson; Jacqueline L Norris-Drouin; Stephanie H Cholensky; Junghyun Lee; Ryan Pasca; Nancy Cheng; Bradley M Dickson; Kenneth H Pearce; Stephen V Frye; Lindsey I James
Journal:  J Med Chem       Date:  2016-09-19       Impact factor: 7.446

Review 7.  Chemical probes for methyl lysine reader domains.

Authors:  Lindsey I James; Stephen V Frye
Journal:  Curr Opin Chem Biol       Date:  2016-06-25       Impact factor: 8.822

8.  Optimization of Ligands Using Focused DNA-Encoded Libraries To Develop a Selective, Cell-Permeable CBX8 Chromodomain Inhibitor.

Authors:  Sijie Wang; Kyle E Denton; Kathryn F Hobbs; Tyler Weaver; James M B McFarlane; Katelyn E Connelly; Michael C Gignac; Natalia Milosevich; Fraser Hof; Irina Paci; Catherine A Musselman; Emily C Dykhuizen; Casey J Krusemark
Journal:  ACS Chem Biol       Date:  2019-12-12       Impact factor: 5.100

Review 9.  The control of polycomb repressive complexes by long noncoding RNAs.

Authors:  Jackson B Trotman; Keean C A Braceros; Rachel E Cherney; McKenzie M Murvin; J Mauro Calabrese
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-04-16       Impact factor: 9.957

10.  Long Noncoding RNA MIR100HG Knockdown Attenuates Hepatocellular Carcinoma Progression by Regulating MicroRNA-146b-5p/Chromobox 6.

Authors:  Fushun Li; Xianghua Sun; Qing Liu; Xilu Liu; Jia Zhang
Journal:  Gastroenterol Res Pract       Date:  2021-07-30       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.